Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data

2001 ◽  
Vol 141 (1) ◽  
pp. 13A-20A ◽  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndromes ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
Intervention Design ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

Bivalirudin and argatroban

2018 ◽  
Author(s):  
Davide Capodanno
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
Heparin Induced Thrombocytopenia ◽  
St Segment Elevation ◽  
St Segment ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

The central role of thrombin in the process of clot formation makes it an important therapeutic target. Heparin is a potent anticoagulant, but has a number of limitations, in that—for example—it does not bind clot-bound thrombin, activates platelets, and may determine heparin-induced thrombocytopenia (HIT). Bivalirudin and argatroban, which belong to the class of intravenous direct thrombin inhibitors, overcome many of the limitations of heparin. Bivalirudin is currently indicated for patients undergoing percutaneous coronary intervention, patients with non-ST-segment elevation acute coronary syndromes planned for urgent or early intervention, and patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Both argatroban and bivalirudin can be used as an alternative to heparin in patients with HIT and HIT-thrombosis syndrome. This chapter describes the current clinical applications of bivalirudin and argatroban.

Sign in / Sign up

Export Citation Format

Share Document